Thursday, September 17, 2026 | UTC
About | Contact | API Status
Sign In Subscribe
Live
AAPL $332.62 +0.06%
MSFT $498.06 +1.58%
GOOGL $347.89 +1.46%
AMZN $252.19 +2.53%
TSLA $371.04 +3.62%
META $674.53 +0.18%
NVDA $219.74 +2.73%
JPM $346.89 -0.58%
BTC $33.92 +0.92%
ETH $23.59 +2.81%
Latest Signing ceremony for contribution agreements between WHO and France Oct 17, 2024
AAPL
$332.62
▲ 0.06%
MSFT
$498.06
▲ 1.58%
GOOGL
$347.89
▲ 1.46%
AMZN
$252.19
▲ 2.53%
TSLA
$371.04
▲ 3.62%
META
$674.53
▲ 0.18%
NVDA
$219.74
▲ 2.73%
JPM
$346.89
▼ 0.58%

Top Stories

Markets →
TechCrunch
DoorDash is opening a limited beta of dd-cli, a command-line tool that lets developers and AI agents search stores, build carts, and place orders from the terminal, marking another step toward software designed for AI agents instead of just humans.
technology  Jul 16, 2026
Bloomberg Markets
Alternative asset manager Balbec Capital LP has obtained commitments of more than $930 million for its latest flagship fund that will invest in a variety of asset-based credit, according to a filing on Thursday.
business  Jul 16, 2026
Bloomberg Markets
Maruti Suzuki India Ltd. said it will challenge a consumer court order asking the nation’s largest carmaker to replace a vehicle over alleged damage from ethanol-blended fuel, a case that assumes significance as the debate over the nation’s biofuel push intensifies.
business  Jul 16, 2026
The Guardian Health
Lipfendra can be taken in conjunction with or an alternative to statins, the most prescribed medication in the USSign up for the Breaking News US newsletter email The drug giant Merck on Thursday announced it had received FDA approval for a daily pill that can be an alternative to statins for treating high LDL levels, or so-called bad cholesterol. The new pill, Lipfendra, is a version of a drug called a PCSK9 inhibitor.For decades the go-to therapy to treat high cholesterol levels has been stati
health  Jul 16, 2026

Stay ahead of the markets.

Get free access to breaking news, stock data, and market analysis.

Subscribe Free